rHDL Technologies

rHDL Therapeutics appears to have been an early-stage biotechnology company or project focused on a reconstituted high-density lipoprotein (rHDL) nanoparticle platform for delivery of RNA therapeutics. Publicly available descriptions indicate the company was developing nanoparticulate systems to carry RNA payloads, including small interfering RNA, for disease indications such as cancer, liver disease, and potentially brain disorders requiring blood-brain barrier penetration. The company was associated with preclinical development activity and NIH SBIR-style grant support, with work involving collaborators at The University of North Texas Health Science Center and The University of Texas MD Anderson Cancer Center. Available evidence suggests it did not progress to a public company or late-stage clinical organization, and current independent company activity is not readily visible. The requested name "rHDL Technologies" most likely refers to this related entity rather than an exact currently active corporate name.